IMM-20059
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


IMM-20059
Bioactivity:
IMM-20059 is a humanized IgG1 monoclonal antibody targeting EPN1. When combined with Atezolizumab, IMM-20059 significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy.Shipping Conditions:
Cool packStorage Temperature:
-20°C
